Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.03. | Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis | 458 | Business Wire | Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31
One-year data from an interim analysis of the OLYMPIA long-term... ► Artikel lesen | |
10.03. | Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis | 560 | Business Wire | Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib's potential role in treating prurigo nodularis... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
NVIDIA | 10.376 |
EVOTEC | 5.243 |
SUPER MICRO COMPUTER | 4.519 |
BAYER | 4.134 |
NEL | 3.729 |
MICROSTRATEGY | 2.718 |
RHEINMETALL | 2.132 |
TESLA | 1.775 |
TUI | 1.747 |
PALANTIR TECHNOLOGIES | 1.463 |
THYSSENKRUPP | 1.411 |
PORSCHE AG | 1.405 |
VOLKSWAGEN | 1.245 |
BIONTECH | 1.206 |
RENK GROUP | 1.199 |
COINBASE GLOBAL | 1.189 |
GAMESTOP | 1.009 |
AIXTRON SE | 979 |
AMAZON | 968 |
SNOWFLAKE | 956 |
COMMERZBANK | 906 |
MERCEDES-BENZ | 904 |
DEUTSCHE BANK | 901 |
BYD | 900 |
BASF | 861 |